A practical reference on lyophilisation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-06. Anything still debated is marked as such rather than presented as settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) tripeptide complex | Contains glycyl-histidyl-lysine ligand |
| Peptide sequence | Gly-His-Lys | N-terminal glycine, C-terminal lysine |
| Molecular formula | C14H22CuN6O4 | Commonly cited for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility | Water-soluble | Also dissolves in some polar solvents |
Quality specifications for research material commonly state peptide purity, copper stoichiometry, counter-ion identity, and residual water content. Frequent counter-ions include acetate and trifluoroacetate, which differ in mass and in their effect on solubility and handling. Whether batch-to-batch differences in reported responses trace to these parameters or to assay conditions remains an open question, since published comparisons rarely control for all of them at once. Independent verification therefore normally pairs a purity measurement with an elemental copper measurement on the same lot.
Practical handling notes centre on limiting exposure to water, oxygen, and repeated temperature cycling. Weighed powder is often equilibrated to room temperature before opening to avoid condensation on the solid. Working solutions are typically divided into single-use aliquots and frozen rather than stored refrigerated for long periods. Reported shelf lives vary widely between laboratories, and no single set of conditions is universally treated as a reference standard, which complicates direct comparison of published stability figures.
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Around 1500 BCE a tribe called the Oenotri ("vine-cultivators"), settled in the region. Ancient sources state they were Greeks who were led to the region by their king, Oenotrus. However it is more likely they were an ancient Italic people who spoke an Italic language. During the eighth and seventh centuries BCE, Greeks founded many settlements on the coast of southern Italy. In Calabria they founded Chone (Pallagorio), Cosentia (Cosenza), Clampetia (Amantea), Scyllaeum (Scilla), Sybaris (Sibari), Hipponion (Vibo Valentia), Epizephyrian Locris (Locri), Kaulon (Monasterace), Krimisa (Cirò Marina), Kroton (Crotone), Laüs (comune of Santa Maria del Cedro), Medma (Rosarno), Metauros (Gioia Tauro), Petelia (Strongoli), Rhégion (Reggio Calabria), Scylletium (Borgia), Temesa (Campora San Giovanni), Terina (Nocera Terinese), Pandosia (Acri) and Thurii, (Thurio, comune of Corigliano Calabro). In the year 744 BCE a group of Chalcidian settlers founded Rhegion (today Reggio Calabria) at the southern end of the peninsula. Soon after, other Chalcidans founded Zancle (current Messina) on the other side of the strait, securing their dominion over that arm of the sea. Later Chalcidian settlers from Rhegion and Zancle founded Metauros (Gioia Tauro) and divided the river of the same name (today Petrace) from the Italic city of the Tauri. In 710 BCE Ionian colonists founded Sybaris on the fertile plain of the same name at the mouth of the Crati.
Greenland Prime Minister Jens-Frederik Nielsen called the deal "gratifying" and "for the benefit of us all." On 22 September 2026, during the general debate of the eighty-first session of the United Nations General Assembly, the United States, Denmark, and Greenland signed a security agreement that increases US involvement in Greenland's defence while affirming Danish sovereignty and Greenland's right to self-determination.
Measurement tools, such as goniometers and inclinometers, aid in standardized quantification of joint motion relative to normative values or ranges. Tests that follow functional movements, such as reaching overhead, squatting, or rotating the neck, are used to evaluate whether reduced ROM translates into activity limitation. When hypomobility is regional, clinicians can use condition-specific values to compare the patient's ROM values against. For instance, in the shoulder, adhesive capsulitis (frozen shoulder) is defined by marked loss of both active and passive motion (particularly external rotation and abduction). For the knee, postoperative arthrofibrosis is typically diagnosed when extension loss exceeds 10° or flexion is limited to less than 100°, with more severe forms showing a flexion deficit of 25° or greater. In the spine, decreased ROM is assessed using values developed for ankylosing spondylitis and related disorders. The Modified Schober Test measures lumbar flexion. An increase of less than 5 cm indicates limited motion, chest expansion of 2.5 cm or less suggests thoracic restriction, and an occiput-to-wall distance greater than 2 cm shows thoracic or cervical extension limitation. The Bath Ankylosing Spondylitis Metrology Index (BASMI) provides a composite score summarizing these spinal mobility measures and is widely used to quantify skeletal hypomobility.
== Prognosis == Prognosis depends on the individual form of muscular dystrophy. Some dystrophies cause progressive weakness and loss of muscle function, which may result in severe physical disability and a life-threatening deterioration of respiratory muscles or heart. Other dystrophies do not affect life expectancy and only cause relatively mild impairment.
Sources: en.wikipedia.org
parietina has more limited genetic exchange between nearby populations than previously thought, possibly due to habitat specialization. Molecular investigations into the mating-type (MAT) loci have further revealed the reproductive strategies within Xanthoria. While X. parietina is homothallic—possessing only a MAT1-2 gene (although truncated)—species such as X. polycarpa are heterothallic, with distinct MAT idiomorphs (different mating-type genetic regions). These differences in mating system structure can significantly affect population genetics, influencing levels of genetic diversity, gene flow, and ultimately speciation processes within the genus.
The Boston keratoprosthesis is the most widely used synthetic cornea to date with over 900 procedures performed worldwide in 2008. The Boston KPro was developed at the Massachusetts Eye and Ear Infirmary under the leadership of Claes Dohlman.
Even the shell structure in the nucleus and electron cloud of oganesson is strongly impacted by relativistic effects: the valence and core electron subshells in oganesson are expected to be "smeared out" in a homogeneous Fermi gas of electrons, unlike those of the "less relativistic" radon and xenon (although there is some incipient delocalisation in radon), due to the very strong spin–orbit splitting of the 7p orbital in oganesson. A similar effect for nucleons, particularly neutrons, is incipient in the closed-neutron-shell nucleus 302Og and is strongly in force at the hypothetical superheavy closed-shell nucleus 472164, with 164 protons and 308 neutrons. Studies have also predicted that due to increasing electrostatic forces, oganesson may have a semibubble structure in proton density, having few protons at the center of its nucleus. Moreover, spin–orbit effects may cause bulk oganesson to be a semiconductor, with a band gap of 1.5±0.6 eV predicted. All the lighter noble gases are insulators instead: for example, the band gap of bulk radon is expected to be 7.1±0.5 eV.
Sources: en.wikipedia.org
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.
Yes, it is found in human plasma, saliva, and urine. Its concentration in plasma tends to decrease with age. This natural presence is one reason researchers have investigated its role in tissue maintenance.
No, GHK-Cu is not an approved drug in major markets. It is widely used as a cosmetic ingredient, where it is listed under names such as copper tripeptide-1. Any therapeutic claims would require separate regulatory review.
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).